Cargando…

MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells

BACKGROUNDS: Trifluridine is an active antitumor component of TAS-102 that resembles 5-fluorouracil. Although patients with advanced colorectal cancer (CRC) exhibiting a mismatch repair (MMR) deficiency reportedly do not benefit from 5-fluorouracil-based chemotherapy and we previously reported that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Satoshi, Iwaizumi, Moriya, Yamada, Hidetaka, Sugiyama, Tomohiro, Hamaya, Yasushi, Furuta, Takahisa, Kanaoka, Shigeru, Sugimura, Haruhiko, Miyajima, Hiroaki, Osawa, Satoshi, Carethers, John M., Sugimoto, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837757/ https://www.ncbi.nlm.nih.gov/pubmed/29545913 http://dx.doi.org/10.18632/oncotarget.22484

Ejemplares similares

DNA mismatch repair is not disrupted in stage 0 colorectal cancer resected using endoscopic submucosal dissection
por: Sugiyama, Tomohiro, et al.
Publicado: (2020)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

High expression level of CD44v8-10 in cancer stem-like cells is associated with poor prognosis in esophageal squamous cell carcinoma patients treated with chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2018)

Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma
por: Mori, Taiki, et al.
Publicado: (2018)

The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy
por: Kagami, Takuma, et al.
Publicado: (2020)

Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report
por: Ishida, Natsuki, et al.
Publicado: (2020)

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone
por: Cleary, James M., et al.
Publicado: (2017)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
por: Lara-Morga, Celia, et al.
Publicado: (2023)

Evaluating mucosal healing using colon capsule endoscopy predicts outcome in patients with ulcerative colitis in clinical remission
por: Takano, Ryosuke, et al.
Publicado: (2018)

Prostaglandin E-major urinary metabolite versus fecal immunochemical occult blood test as a biomarker for patient with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2020)

Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
por: Ishida, Natsuki, et al.
Publicado: (2021)

Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
por: TANAKA, NOZOMU, et al.
Publicado: (2014)

Panitumumab interaction with TAS‐102 leads to combinational anticancer effects via blocking of EGFR‐mediated tumor response to trifluridine
por: Baba, Yuji, et al.
Publicado: (2017)

Photodynamic Therapy Using Talaporfin Sodium for Local Failure after Chemoradiotherapy or Radiotherapy for Esophageal Cancer: A Single Center Experience
por: Ishida, Natsuki, et al.
Publicado: (2020)

Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
por: Ishida, Natsuki, et al.
Publicado: (2021)

C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021)

Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission
por: Miyazu, Takahiro, et al.
Publicado: (2021)

Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
por: Tamura, Satoshi, et al.
Publicado: (2020)

Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis
por: Tamura, Satoshi, et al.
Publicado: (2021)

Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy
por: Ishida, Natsuki, et al.
Publicado: (2022)

Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2022)

Modified method of patency judgement using patency capsule prior to capsule endoscopy in clinical practice
por: Miyazu, Takahiro, et al.
Publicado: (2022)

A comparison of two types of contrast media used in endoscopic retrograde cholangiopancreatography: A retrospective study
por: Matsuura, Tomoharu, et al.
Publicado: (2023)

Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
por: Furuta, Takahisa, et al.
Publicado: (2023)

Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study
por: Ishida, Natsuki, et al.
Publicado: (2021)

Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
por: Ishida, Natsuki, et al.
Publicado: (2020)

Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease
por: Ishida, Natsuki, et al.
Publicado: (2021)

Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study
por: Miyazu, Takahiro, et al.
Publicado: (2022)

The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2020)

Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
por: Ishida, Natsuki, et al.
Publicado: (2022)

Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
por: Ishida, Natsuki, et al.
Publicado: (2022)

The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
por: Van Cutsem, Eric, et al.
Publicado: (2017)

Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases
por: Fidelman, Nicholas, et al.
Publicado: (2022)

Methylation of CpG island promoters at ZNF625, LONRF2, SDC2 and WDR17 in a patient with numerous non-granular type laterally spreading tumors and colorectal cancer: A case report
por: Iwaizumi, Moriya, et al.
Publicado: (2022)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme
por: Sforza, Vincenzo, et al.
Publicado: (2017)

Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma
por: Osawa, Satoshi, et al.
Publicado: (2009)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cl4d239dbbc4hfn2fs02ph12j7